Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome.
- 2016-01
- RCT · n = 41
- European journal of gastroenterology & hepatology 28(1)
- Annemieke Y Thijssen
- Cees H M Clemens
- Vanessa Vankerckhoven
- Herman Goossens
- Daisy M A E Jonkers
- Ad A M Masclee
- PubMed: 26469356
- DOI: 10.1097/meg.0000000000000484
- High evidence
- Clinical
After the intervention period, the mean relative improvement did not reach 30% for MSS or any individual symptom score. After follow-up (week 16), a mean improvement of at least 30% was achieved for MSS in the probiotic group, but no significant difference was found between both treatment groups (mean±SD: 34±7%; 13±8%, P=0.06).
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- twice daily